



## **Hikma becomes Harvard Business School Case Study as Part of Corporate Governance and Making Boards Effective Modules**

**London, 06 March 2018** – Hikma Pharmaceuticals PLC (Hikma, Group) (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (rated Ba1 Moody's / BB+ S&P, both stable), has become the subject of a case study at Harvard Business School for use in courses on corporate governance and boards of directors in both the MBA and executive education programs. The Hikma case study will be used to illustrate the governance transition that a family business undertakes to become a publicly traded company.

Members of the Board of Directors as well as the management team were interviewed for the case study. Said Darwazah, Executive Chairman of Hikma said "We are extremely proud and very honoured that Harvard Business School has selected Hikma as a case study for its students. It is particularly gratifying to know that students will learn about establishing strong corporate governance from our experience of transitioning from a family business to a public company on the London Stock Exchange."

The Hikma business case was written by Harvard Professors Lynn Paine and Suraj Srinivasan and research associate Gamze Yucaoglu. Professors Paine and Srinivasan both teach the executive program called "Making Corporate Boards More Effective." The Hikma case will be used for the first time in the spring of 2018.

The Hikma case study should be available soon at <http://hbsp.harvard.edu/product/cases>.

-- ENDS --

### **Hikma Pharmaceuticals PLC**

Susan Ringdal, VP Corporate Strategy and Investor Relations +44 (0)20 7399 2760/ +44 (0)7776 477050

Virginia Spring, Investor Relations Manager +44 (0)20 3892 4389/ +44 (0)7973 679502

### **FTI Consulting**

Ben Atwell/Brett Pollard +44 (0)20 3727 1000

### **About Hikma**

Hikma Pharmaceuticals PLC is a pharmaceutical group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed products. Hikma's operations are conducted through three businesses: 'Branded', 'Injectables' and 'Generics' based primarily in the Middle East and North Africa (MENA), the United States and Europe.